With Hologic, Inc. (HOLX) gearing up to release its fiscal 2025 first-quarter financial results on Feb. 5 after the market closes, the company’s Breast Health segment is expected to have benefited from gantry and imaging service businesses and the expanding interventional portfolio. The Diagnostics division is expected to have gained from the strong Molecular Diagnostics momentum. Additionally, international sales may have bolstered the GYN Surgical segment’s performance.Stay up-to-date with all quarterly r ...

Hologic (HOLX) is set to release first-quarter fiscal 2025 results on Feb. 5 after the closing bell.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.The Zacks Consensus Estimate for first-quarter earnings suggests a 3.1% increase year over year to $1.01 per share. The estimate has remained stable in the past 30 days. The Zacks Consensus Estimate for first-quarter revenues currently stands at $1.03 billion, a 1.4% improvement compared to the last year.Image Source: Zacks Investment Re ...

Stock Performance - Hologic (HOLX) closed at $71 19, marking a +1 17% increase from the previous day, outperforming the S&P 500's 0 61% gain and the Nasdaq's 1 28% gain [1] - Over the past month, HOLX stock dropped by 3 18%, underperforming the Medical sector's gain of 1 64% and the S&P 500's gain of 2 08% [1] Earnings and Revenue Expectations - The company is expected to report Q4 2025 EPS of $1 01, a 3 06% increase from the prior-year quarter, with revenue expected to be $1 03 billion, up 1 39% year-over-year [2] - Full-year Zacks Consensus Estimates predict earnings of $4 27 per share and revenue of $4 17 billion, representing year-over-year changes of +4 66% and +3 48%, respectively [3] Analyst Estimates and Revisions - Recent revisions to analyst estimates reflect near-term business trends, with positive alterations indicating optimism about the company's profitability [3] - Over the past month, the Zacks Consensus EPS estimate for HOLX has moved 0 31% lower, and the stock currently holds a Zacks Rank of 3 (Hold) [5] Valuation Metrics - HOLX has a Forward P/E ratio of 16 47, representing a discount compared to the industry average Forward P/E of 28 55 [6] - The company's PEG ratio is 2 4, slightly higher than the Medical - Instruments industry average of 2 26 [7] Industry Performance - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 60, placing it in the top 24% of all industries [7] - Research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we are putting Hologic, Inc. (NASDAQ: HOLX ) in the spotlight. It is my first deeper dive into this large diagnostic concern since my article on it back in November 2023. Th ...

Shares of Hologic (HOLX) recorded a new 52-week low of $69.46 during Monday’s trading before finishing slightly higher at $70.29. Yesterday, the stock ended at $70.20, marking the lowest close in recent sessions. The latest drop in the share price can be attributed to the company’s mixed preliminary revenue results for the fiscal 2025 first quarter, released earlier this week.In the past six months, Hologic shares have dipped 12%, steeper than the industry’s 0.6% fall and the broader market’s 11.1% decline. ...

The most recent trading session ended with Hologic (HOLX) standing at $72.73, reflecting a +0.05% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily gain of 0.16%. On the other hand, the Dow registered a gain of 0.25%, and the technology-centric Nasdaq decreased by 0.06%.Coming into today, shares of the medical device maker had lost 5.39% in the past month. In that same time, the Medical sector lost 5.77%, while the S&P 500 lost 2.8%.The upcoming earnings ...

Hologic, Inc. (HOLX) announced that it has completed the previously announced acquisition of Gynesonics, Inc. — a privately held medical device company focused on developing minimally invasive solutions for women’s health. Hologic acquired Gynesonics for approximately $350 million. The latest acquisition is aimed at strengthening Hologic’s GYN Surgical business segment.Likely Trend of HOLX Stock Following the NewsFollowing the announcement, shares of the company surged 0.8% to $73.77 yesterday.The transform ...

Hologic (HOLX) closed at $72.68 in the latest trading session, marking no change from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.04%. Elsewhere, the Dow gained 0.07%, while the tech-heavy Nasdaq lost 0.05%.Heading into today, shares of the medical device maker had lost 8.51% over the past month, lagging the Medical sector's loss of 4.31% and the S&P 500's gain of 1.05% in that time.The investment community will be paying close attention to the earnings performance ...

Hologic, Inc. (HOLX) recently entered into an agreement with the Centers for Disease Control and Prevention (“CDC”) to develop analyte-specific reagents (ASRs) — the “active ingredients” of laboratory-developed tests aimed at detecting H5N1 bird flu. The ASRs are being developed on the company’s Panther Fusion system, a fully automated molecular testing platform that allows labs to quickly consolidate and run multiple assays for women's health, infectious disease and SARS-CoV-2 (COVID-19) testing.The latest ...

Hologic (HOLX) closed at $70.76 in the latest trading session, marking a -0.99% move from the prior day. This change lagged the S&P 500's 0.09% loss on the day. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq lost 0.1%.Prior to today's trading, shares of the medical device maker had lost 8.42% over the past month. This has lagged the Medical sector's loss of 2.1% and the S&P 500's loss of 0.29% in that time.Investors will be eagerly watching for the performance of Hologic in its upcoming earnin ...